PreveCeutical Announces Successful Completion of its Sol-gel Program
Wednesday, June 3, 2020, 7:00 AM ET
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program").
The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery of cannabinoid extracts ("CBDs"). Soluble gels (solgels) present an ideal platform for achieving this aim, being in-solution upon administration, and rapidly gelling upon contact with mucosal tissue, paving the way for safer, reliable drug delivery for agents, such as CBDs that are rapidly metabolized, or that would benefit from direct nose-to-brain CNS delivery to provide clinical benefit.
Cannabis is currently generating considerable interest in medical research to treat illnesses or symptoms across epilepsy, neuropathic pain, multiple sclerosis, palliative care associated with AIDS, cachexia and appetite enhancement, cancer and chemotherapy-induced nausea and vomiting, Crohn's disease and glaucoma.
The Company is planning on developing lead cannabinoid formulations that may provide therapies aiming to address the various illnesses with plans to commercialize after clinical trials have been conducted.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain any of the ailments listed above, at this time.
The Company will provide further upon when the final Sol-Gel Program report is received from UniQuest Pty Limited. This will allow PreveCeutical to file patents to secure our intellectual property derived from this program.
PreveCeutical's President and Chief Science Officer, Dr. Mak Jawadekar, stated, "Completion of the CBD Sol-Gel Program is a very significant milestone achievement for PreveCeutical. We are very excited about the therapeutic opportunities that will be derived from the program and look forward to progressing them through proof of concept studies".